Nothing Special   »   [go: up one dir, main page]

Holsboer, 2001 - Google Patents

Antidepressant drug discovery in the postgenomic era

Holsboer, 2001

View PDF
Document ID
15447171733442589213
Author
Holsboer F
Publication year
Publication venue
The World Journal of Biological Psychiatry

External Links

Snippet

The progress made in genome research raises the question whether the new knowledge bases that have emerged may also lead to better antidepressants. The past has seen many remarkable improvements over traditional drugs, but not a real breakthrough. More recently …
Continue reading at citeseerx.ist.psu.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Similar Documents

Publication Publication Date Title
Holsboer Antidepressant drug discovery in the postgenomic era
Raghavan et al. Whole‐exome sequencing in 20,197 persons for rare variants in Alzheimer's disease
Kim et al. Axon regeneration in young adult mice lacking Nogo-A/B
Wu et al. Dorsal root ganglion transcriptome analysis following peripheral nerve injury in mice
Talwar et al. Dissecting complex and multifactorial nature of Alzheimer’s disease pathogenesis: a clinical, genomic, and systems biology perspective
Semple et al. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks
Girotto et al. Hearing function and thresholds: a genome-wide association study in European isolated populations identifies new loci and pathways
Tzouvelekis et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1α in disease pathogenesis
Kubota-Sakashita et al. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia
Marshe et al. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
Fleck et al. PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease
US10837062B2 (en) Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms
KR20090019848A (en) Biomarkers for the progression of alzheimer's disease
US20200095280A1 (en) Methods of using GM6 in diagnosing and treating Alzheimers disease
Liu et al. Identification of hub genes and small-molecule compounds related to intracerebral hemorrhage with bioinformatics analysis
Holsboer Prospects for antidepressant drug discovery
Zubenko et al. Differential hippocampal gene expression and pathway analysis in an etiology‐based mouse model of major depressive disorder
Vélez et al. Mutations modifying sporadic Alzheimer's disease age of onset
Berger et al. APOE4 copy number-dependent proteomic changes in the cerebrospinal fluid
CN101516401A (en) Biomarkers for Alzheimer's disease progression
Krishnaraj et al. Genome‐wide transcriptomic and proteomic studies of Rett syndrome mouse models identify common signaling pathways and cellular functions as potential therapeutic targets
Shadrach et al. Translatomic analysis of regenerating and degenerating spinal motor neurons in injury and ALS
Sleegers et al. Molecular pathways of frontotemporal lobar degeneration
JP2009515542A (en) Biomarker for anti-Nogo-A antibody treatment in spinal cord injury
Fadahunsi et al. Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment